Nautilus Biotechnology, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:NAUT
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 201 out of 861
Universe
Global Universe 7676 out of 15172
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Nautilus Biotechnology, Inc. |
25.7
Medium
|
201 out of 861 |
GeneOne Life Science, Inc. |
29.5
Medium
|
370 out of 861 |
Seer, Inc. (California) |
30.6
High
|
425 out of 861 |
CG Invites Co., Ltd. |
32.9
High
|
527 out of 861 |
Lineage Cell Therapeutics, Inc. |
40.3
Severe
|
820 out of 861 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Nautilus Biotechnology, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Nautilus Biotechnology, Inc.'s Management of ESG Material Risk is Average